ASH 2023 | The potential of combination therapies to improve CAR-T outcomes in patients with CLL
Tanya Siddiqi, MD, City of Hope, Duarte, CA, explores avenues to enhance the efficacy of CAR-T therapies in chronic lymphocytic leukemia (CLL). She suggests combining BTK inhibitors, such as ibrutinib, with CAR T-cells as a potential strategy to improve outcomes. This has previously been done in a cohort of patients on the Phase I portion of the TRANSCEND-CLL-004 trial (NCT03331198) of lisocabtagene maraleucel (liso-cel) in CLL. At present, results from this trial are not yet available, and further trials will be necessary to investigate this combination of agents. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
That’s a very good question. We certainly want to do better than 20% CR rates. So obviously that’s our next sort of mission, if you will, to kind of see how we can do better. We did have a cohort on the Phase I portion of this study where we combined ibrutinib with the liso-cel CAR T-cells. We don’t have results on that yet. Hopefully, we’ll see results in 2024 of that cohort...
That’s a very good question. We certainly want to do better than 20% CR rates. So obviously that’s our next sort of mission, if you will, to kind of see how we can do better. We did have a cohort on the Phase I portion of this study where we combined ibrutinib with the liso-cel CAR T-cells. We don’t have results on that yet. Hopefully, we’ll see results in 2024 of that cohort. And if we notice that that adds a lot more to the benefit of CAR T-cells, then, of course, that may be one way to go. Combination with a BTK inhibitor to kind of potentiate the CAR T-cells and see if you can have deeper and more durable responses. So, that work still needs to be done. We need to improve upon CAR T-cells even further, but, at this point, I don’t have the answer.
Read more...
Disclosures
Consultancy: Juno therapeutics, AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
Research Funding: Juno therapeutics, TG therapeutics, Oncternal, Pharmacyclics, LLC an AbbVie Company, Ascentage Pharma, Kite Pharma, Celgene, BeiGene, AstraZeneca
Speakers Bureau: Janssen, BeiGene, AstraZeneca, BMS
Board of Directors/Advisory Committee: AbbVie, Kite Pharma, Celgene, BeiGene, AstraZeneca, BMS
